Toggle Main Menu Toggle Search

Open Access padlockePrints

Synucleinopathies: Where we are and where we need to go

Lookup NU author(s): Dr David KossORCiD, Professor Tiago OuteiroORCiD



This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


© 2020 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry. Synucleinopathies are a group of disorders characterized by the accumulation of inclusions rich in the a-synuclein (aSyn) protein. This group of disorders includes Parkinson's disease, dementia with Lewy bodies (DLB), multiple systems atrophy, and pure autonomic failure (PAF). In addition, genetic alterations (point mutations and multiplications) in the gene encoding for aSyn (SNCA) are associated with familial forms of Parkinson's disease, the most common synucleinopathy. The Synuclein Meetings are a series that has been taking place every 2 years for about 12 years. The Synuclein Meetings bring together leading experts in the field of Synuclein and related human conditions with the goal of discussing and advancing the research. In 2019, the Synuclein meeting took place in Ofir, a city in the outskirts of Porto, Portugal. The meeting, entitled "Synuclein Meeting 2019: Where we are and where we need to go", brought together >300 scientists studying both clinical and molecular aspects of synucleinopathies. The meeting covered a many of the open questions in the field, in a format that prompted open discussions between the participants, and underscored the need for additional research that, hopefully, will lead to future therapies for a group of as of yet incurable disorders. Here, we provide a summary of the topics discussed in each session and highlight what we know, what we do not know, and what progress needs to be made in order to enable the field to continue to advance. We are confident this systematic assessment of where we stand will be useful to steer the field and contribute to filling knowledge gaps that may form the foundations for future therapeutic strategies, which is where we need to go. (Figure presented.).

Publication metadata

Author(s): Bras IC, Dominguez-Meijide A, Gerhardt E, Koss D, Lazaro DF, Santos PI, Vasili E, Xylaki M, Outeiro TF

Publication type: Review

Publication status: Published

Journal: Journal of Neurochemistry

Year: 2020

Volume: 153

Issue: 4

Pages: 433-454

Print publication date: 01/05/2020

Online publication date: 20/01/2020

Acceptance date: 08/01/2020

ISSN (print): 0022-3042

ISSN (electronic): 1471-4159

Publisher: Blackwell Publishing Ltd


DOI: 10.1111/jnc.14965

PubMed id: 31957016